These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 16028352)

  • 1. Physical stability and solubility advantage from amorphous celecoxib: the role of thermodynamic quantities and molecular mobility.
    Gupta P; Chawla G; Bansal AK
    Mol Pharm; 2004; 1(6):406-13. PubMed ID: 16028352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stability and solubility of celecoxib-PVP amorphous dispersions: a molecular perspective.
    Gupta P; Kakumanu VK; Bansal AK
    Pharm Res; 2004 Oct; 21(10):1762-9. PubMed ID: 15553220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of amorphous celecoxib stability by mixing it with octaacetylmaltose: the molecular dynamics study.
    Grzybowska K; Paluch M; Wlodarczyk P; Grzybowski A; Kaminski K; Hawelek L; Zakowiecki D; Kasprzycka A; Jankowska-Sumara I
    Mol Pharm; 2012 Apr; 9(4):894-904. PubMed ID: 22384922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Devitrification of amorphous celecoxib.
    Gupta P; Bansal AK
    AAPS PharmSciTech; 2005 Sep; 6(2):E223-30. PubMed ID: 16353981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ternary amorphous composites of celecoxib, poly(vinyl pyrrolidone) and meglumine with enhanced solubility.
    Gupta P; Bansal AK
    Pharmazie; 2005 Nov; 60(11):830-6. PubMed ID: 16320944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thermodynamic behavior of glassy state of structurally related compounds.
    Kaushal AM; Bansal AK
    Eur J Pharm Biopharm; 2008 Aug; 69(3):1067-76. PubMed ID: 18420396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Factors Governing the Liquid and Glassy States Recrystallization of Celecoxib in Binary Mixtures with Excipients of Different Molecular Weights.
    Grzybowska K; Chmiel K; Knapik-Kowalczuk J; Grzybowski A; Jurkiewicz K; Paluch M
    Mol Pharm; 2017 Apr; 14(4):1154-1168. PubMed ID: 28241116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physical stability of amorphous pharmaceuticals: Importance of configurational thermodynamic quantities and molecular mobility.
    Zhou D; Zhang GG; Law D; Grant DJ; Schmitt EA
    J Pharm Sci; 2002 Aug; 91(8):1863-72. PubMed ID: 12115813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling of drug release from celecoxib-PVP-meglumine amorphous systems.
    Gupta P; Bansal AK
    PDA J Pharm Sci Technol; 2005; 59(6):346-54. PubMed ID: 16471422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of molecular interaction in stability of celecoxib-PVP amorphous systems.
    Gupta P; Thilagavathi R; Chakraborti AK; Bansal AK
    Mol Pharm; 2005; 2(5):384-91. PubMed ID: 16196491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enthalpy relaxation studies of celecoxib amorphous mixtures.
    Kakumanu VK; Bansal AK
    Pharm Res; 2002 Dec; 19(12):1873-8. PubMed ID: 12523668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular dynamics and physical stability of amorphous anti-inflammatory drug: celecoxib.
    Grzybowska K; Paluch M; Grzybowski A; Wojnarowska Z; Hawelek L; Kolodziejczyk K; Ngai KL
    J Phys Chem B; 2010 Oct; 114(40):12792-801. PubMed ID: 20849135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Celecoxib:nicotinamide dissociation: using excipients to capture the cocrystal's potential.
    Remenar JF; Peterson ML; Stephens PW; Zhang Z; Zimenkov Y; Hickey MB
    Mol Pharm; 2007; 4(3):386-400. PubMed ID: 17497886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of advanced thermal analysis for characterization of crystalline and amorphous phases of carvedilol.
    Skotnicki M; Czerniecka-Kubicka A; Neilsen G; Woodfield BF; Pyda M
    J Pharm Biomed Anal; 2022 Aug; 217():114822. PubMed ID: 35550491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What is the true solubility advantage for amorphous pharmaceuticals?
    Hancock BC; Parks M
    Pharm Res; 2000 Apr; 17(4):397-404. PubMed ID: 10870982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of different "states" of sorbed water on amorphous celecoxib.
    Shete G; Kuncham S; Puri V; Gangwal RP; Sangamwar AT; Bansal AK
    J Pharm Sci; 2014 Jul; 103(7):2033-2041. PubMed ID: 24801826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential molecular interactions between the crystalline and the amorphous phases of celecoxib.
    Gupta P; Thilagavathi R; Chakraborti AK; Bansal AK
    J Pharm Pharmacol; 2005 Oct; 57(10):1271-8. PubMed ID: 16259755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A calorimetric investigation of thermodynamic and molecular mobility contributions to the physical stability of two pharmaceutical glasses.
    Zhou D; Grant DJ; Zhang GG; Law D; Schmitt EA
    J Pharm Sci; 2007 Jan; 96(1):71-83. PubMed ID: 17031846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of calcined Mg-Al-hydrotalcite to enhance the stability of celecoxib in the amorphous form.
    Ambrogi V; Perioli L; Marmottini F; Rossi C
    Eur J Pharm Biopharm; 2007 May; 66(2):253-9. PubMed ID: 17123798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crystallization kinetics and molecular mobility of an amorphous active pharmaceutical ingredient: A case study with Biclotymol.
    Schammé B; Couvrat N; Malpeli P; Delbreilh L; Dupray V; Dargent É; Coquerel G
    Int J Pharm; 2015 Jul; 490(1-2):248-57. PubMed ID: 26003417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.